VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

10 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors

09 май 2023 07:00:02 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

08 май 2023 07:08:44 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101

30 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Stifel 2023 CNS Days

22 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

21 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting

02 мар 2023 16:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team

15 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP

14 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022

28 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

10 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming Investor Conferences

07 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

02 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

01 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference

01 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces $75 Million Private Placement Financing

12 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

08 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

02 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.

28 июл 2022 07:00:01 Источник Nasdaq GlobeNewswire